Prima BioMed, NEC, Yamaguchi University deal

Prima, NEC and the university partnered to conduct a preclinical study of Prima’s IMP321 as an adjuvant in combination with a peptide vaccine developed by NEC and the university to treat hepatocellular cancer (HCC). The university will conduct the study, which NEC will support. Prima declined to disclose the specific nature of the vaccine and financial terms. ...